Patient-derived orthotopic xenograft models of sarcoma

Kentaro Igarashi, Kei Kawaguchi, Takashi Murakami, Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, Yukihiko Hiroshima, Takashi Higuchi, Hiromichi Oshiro, Scott D. Nelson, Sarah M. Dry, Yunfeng Li, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M. Hoffman

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)


Sarcoma is a rare and recalcitrant malignancy. Although immune and novel targeted therapies have been tested on many cancer types, few sarcoma patients have had durable responses with such therapy. Doxorubicin and cisplatinum are still first-line chemotherapy after four decades. Our laboratory has established the patient-derived orthotopic xenograft (PDOX) model using surgical orthotopic implantation (SOI). Many promising results have been obtained using the sarcoma PDOX model for identifying effective approved drugs and experimental therapeutics, as well as combinations of them for individual patients. In this review, we present our laboratory's experience with PDOX models of sarcoma, and the ability of the PDOX models to identify effective approved agents, as well as experimental therapeutics.

Original languageEnglish
Pages (from-to)332-339
Number of pages8
JournalCancer Letters
Publication statusPublished - 2020 Jan 28
Externally publishedYes


  • Individualized therapy
  • PDOX
  • Patient-derived sarcoma
  • Precision medicine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Patient-derived orthotopic xenograft models of sarcoma'. Together they form a unique fingerprint.

Cite this